Prevalence investigation of plasma cell leukemia in China: a calculation based on national urban medical insurance in 2016
10.3760/cma.j.issn.0253-2727.2020.12.003
- VernacularTitle:中国浆细胞白血病的患病率调查:基于全国2016年城镇医疗保险数据的测算
- Author:
Lu XU
1
;
Yang LIU
;
Xuefeng LAI
;
Yi BAI
;
Jingnan FENG
;
Siyan ZHAN
;
Xiaojun HUANG
;
Shengfeng WANG
;
Jin LU
Author Information
1. 北京大学公共卫生学院流行病与卫生统计学系，北京 100191
- Keywords:
Plasma cell leukemia;
Prevalence;
Medical insurance
- From:
Chinese Journal of Hematology
2020;41(12):984-988
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the epidemiological features of patients with plasma cell leukemia (PCL) and calculate the prevalence of PCL in urban China in 2016.Methods:Calculation in this study was based on China's urban basic medical insurance from 23 provinces between January 1, 2016 and December 31, 2016. The identification of the patients with PCL was based on the disease names and codes in the claim data. Subgroup analyses were carried out by sex, region, and age. To test the robustness of the results, we performed sensitivity analyses. Age-adjusted prevalence was calculated, based on the 2010 Chinese census data.Results:The prevalence of PCL in urban China in 2016 was 0.11 per 100 000 population (95% CI 0.05-0.19) , and the male prevalence and female prevalence were 0.12 per 100 000 population (95% CI 0.06-0.21) and 0.10 per 100 000 population (95% CI 0.04-0.19) , respectively. The prevalence of PCL peaked at 70-79 years old. Sensitivity analyses proved the robustness of the primary result. The age-adjusted prevalence based on 2010 Chinese census data was 0.12 per 100 000 population (95% CI 0.11-0.13) . Conclusion:This study firstly analyzed the epidemiological characteristics of PCL in China, which can provide evidence for the research and policies regarding PCL.
